Monday 2 Oct 2017: Update on FDA Review of Bleeding Disorder Treatment
the South San Francisco, Calif.-based firm said the U.S. Food and Drug Administration indicated that it does not plan to conduct an Oncology Drugs Advisory Committee meeting to discuss Rigel's new drug application for fostamatinib in chronic or persistent immune thrombocytopenia.
No comments:
Post a Comment